ABSTRACT: This SuperSeries is composed of the following subset Series: GSE28335: Melanoma cell culture phenotypes I GSE33727: Melanoma cell culture phenotypes II Refer to individual Series
Project description:Recent trials with MAPK inhibitors have shown promising results in many patients with metastatic melanoma; however, nearly all responding patients experience disease relapse. We describe here how melanoma cells respond to MAPK inhibition in a phenotype-specific manner, suggesting that slow cycling invasive phenotype cells provide a treatment-resistant pool from which disease relapse may be derived. The implication is that while MAPK inhibition may successfully treat proliferating cells, another cell population needs to be addressed at the same time. 12 samples
Project description:This SuperSeries is composed of the following subset Series: GSE21505: Expression analysis of melanoma harvested from GFP versus SETDB1 transgenic zebrafish (Danio rerio) GSE26371: Expression analysis of human melanoma short-term culture WM451-Lu harvested after lentiviral infection with a GFP (control) or SETDB1 (experimental) viral vector Refer to individual Series
Project description:S100A4 is a known metastasis-promoting factor, rich in the tumor microenvironment. To clarify how extracellular S100A4 execute its pro-metastatic function, we analyzed gene expression in melanoma cells stimulated with recombinant protein rS100A4 and compared it to the expression in control non-stimulated cells. Two melanoma cell lines representing two distinct phenotypes M-bM-^@M-^S invasive (Melmet 1) and non-invasive/proliferative (Melmet 5) M-bM-^@M-^S were included in the study. The response at the gene expression level was much stronger in Melmet 5 than in Melmet 1. Melmet 5 down-regulated genes associated with melanocytic differentiation, indicating that Melmet 5 cells gained dedifferentiated, more invasive phenotype after stimulation with rS100A4. The observed changes in the expression of metabolism associated genes suggested the occurrence of metabolic reprogramming. We conclude that extracellular S100A4 stimulate the transition to the invasive phenotype in poorly-invasive melanoma cells, and that this transition is associated with metabolic reprogrammingve Total RNA was isolated from Melmet 1 and Melmet 5 cells stimulated with rS100A4 protein for 48hrs compared to non-stimulated cells.
Project description:S100A4 is a known metastasis-promoting factor, rich in the tumor microenvironment. To clarify how extracellular S100A4 execute its pro-metastatic function, we analyzed gene expression in melanoma cells stimulated with recombinant protein rS100A4 and compared it to the expression in control non-stimulated cells. Two melanoma cell lines representing two distinct phenotypes – invasive (Melmet 1) and non-invasive/proliferative (Melmet 5) – were included in the study. The response at the gene expression level was much stronger in Melmet 5 than in Melmet 1. Melmet 5 down-regulated genes associated with melanocytic differentiation, indicating that Melmet 5 cells gained dedifferentiated, more invasive phenotype after stimulation with rS100A4. The observed changes in the expression of metabolism associated genes suggested the occurrence of metabolic reprogramming. We conclude that extracellular S100A4 stimulate the transition to the invasive phenotype in poorly-invasive melanoma cells, and that this transition is associated with metabolic reprogrammingve
Project description:These samples are part of a study that tries to find melanoma subgroups by the mean of gene expression analysis. Recent trials with MAPK inhibitors have shown promising results in many patients with metastatic melanoma; however, nearly all responding patients experience disease relapse. We describe here how melanoma cells respond to MAPK inhibition in a phenotype-specific manner, suggesting that slow cycling invasive phenotype cells provide a treatment-resistant pool from which disease relapse may be derived. The implication is that while MAPK inhibition may successfully treat proliferating cells, another cell population needs to be addressed at the same time.
Project description:Recent trials with MAPK inhibitors have shown promising results in many patients with metastatic melanoma; however, nearly all responding patients experience disease relapse. We describe here how melanoma cells respond to MAPK inhibition in a phenotype-specific manner, suggesting that slow cycling invasive phenotype cells provide a treatment-resistant pool from which disease relapse may be derived. The implication is that while MAPK inhibition may successfully treat proliferating cells, another cell population needs to be addressed at the same time.
Project description:This SuperSeries is composed of the following subset Series: GSE35387: Expression data from normal melanocyte, melanoma cells and their exosomes (microRNA) GSE35388: Expression data from normal melanocyte, melanoma cells and their exosomes (mRNA) Refer to individual Series